Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Position Statements

14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2020

  1. American Diabetes Association
Diabetes Care 2020 Jan; 43(Supplement 1): S183-S192. https://doi.org/10.2337/dc20-S014
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Abstract

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

DIABETES IN PREGNANCY

The prevalence of diabetes in pregnancy has been increasing in the U.S. in parallel with the worldwide epidemic of obesity. Not only is the prevalence of type 1 diabetes and type 2 diabetes increasing in women of reproductive age, but there is also a dramatic increase in the reported rates of gestational diabetes mellitus. Diabetes confers significantly greater maternal and fetal risk largely related to the degree of hyperglycemia but also related to chronic complications and comorbidities of diabetes. In general, specific risks of diabetes in pregnancy include spontaneous abortion, fetal anomalies, preeclampsia, fetal demise, macrosomia, neonatal hypoglycemia, hyperbilirubinemia, and neonatal respiratory distress syndrome, among others. In addition, diabetes in pregnancy may increase the risk of obesity, hypertension, and type 2 diabetes in offspring later in life (1,2).

PRECONCEPTION COUNSELING

Recommendations

  • 14.1 Starting at puberty and continuing in all women with diabetes and reproductive potential, preconception counseling should be incorporated into routine diabetes care. A

  • 14.2 Family planning should be discussed, and effective contraception (with consideration of long-acting, reversible contraception) should be prescribed and used until a woman’s treatment regimen and A1C are optimized for pregnancy. A

  • 14.3 Preconception counseling should address the importance of achieving glucose levels as close to normal as is safely possible, ideally A1C <6.5% (48 mmol/mol), to reduce the risk of congenital anomalies, preeclampsia, macrosomia, and other complications. B

All women of childbearing age with diabetes should be informed about the importance of achieving and maintaining as near euglycemia as safely possible prior to conception and throughout pregnancy. Observational studies show an increased risk of diabetic embryopathy, especially anencephaly, microcephaly, congenital heart disease, renal anomalies, and caudal regression, directly proportional to elevations in A1C during the first 10 weeks of pregnancy (3). Although observational studies are confounded by the association between elevated periconceptional A1C and other poor self-care behavior, the quantity and consistency of data are convincing and support the recommendation to optimize glycemia prior to conception, given that organogenesis occurs primarily at 5–8 weeks of gestation, with an A1C <6.5% (48 mmol/mol) being associated with the lowest risk of congenital anomalies (3–6).

There are opportunities to educate all women and adolescents of reproductive age with diabetes about the risks of unplanned pregnancies and about improved maternal and fetal outcomes with pregnancy planning (7). Effective preconception counseling could avert substantial health and associated cost burdens in offspring (8). Family planning should be discussed, including the benefits of long-acting, reversable contraception, and effective contraception should be prescribed and used until a woman is prepared and ready to become pregnant (9–13).

To minimize the occurrence of complications, beginning at the onset of puberty or at diagnosis, all girls and women with diabetes of childbearing potential should receive education about 1) the risks of malformations associated with unplanned pregnancies and even mild hyperglycemia and 2) the use of effective contraception at all times when preventing a pregnancy. Preconception counseling using developmentally appropriate educational tools enables adolescent girls to make well-informed decisions (7). Preconception counseling resources tailored for adolescents are available at no cost through the American Diabetes Association (ADA) (14).

Preconception Care

Recommendations

  • 14.4 Women with preexisting diabetes who are planning a pregnancy should ideally be managed beginning in preconception in a multidisciplinary clinic including an endocrinologist, maternal-fetal medicine specialist, registered dietitian nutritionist, and diabetes educator, when available. B

  • 14.5 In addition to focused attention on achieving glycemic targets A, standard preconception care should be augmented with extra focus on nutrition, diabetes education, and screening for diabetes comorbidities and complications. E

  • 14.6 Women with preexisting type 1 or type 2 diabetes who are planning pregnancy or who have become pregnant should be counseled on the risk of development and/or progression of diabetic retinopathy. Dilated eye examinations should occur ideally before pregnancy or in the first trimester, and then patients should be monitored every trimester and for 1 year postpartum as indicated by the degree of retinopathy and as recommended by the eye care provider. B

The importance of preconception care for all women is highlighted by the American College of Obstetricians and Gynecologists (ACOG) committee opinion 762, Prepregnancy Counseling (15). A key point is the need to incorporate a question about a woman’s plans for pregnancy into routine primary and gynecologic care. The preconception care of women with diabetes should include the standard screenings and care recommended for all women planning pregnancy (15). Prescription of prenatal vitamins (with at least 400 mg of folic acid and 150 μg of potassium iodide [16]) is recommended prior to conception. Review and counseling on the use of nicotine products, alcohol, and recreational drugs, including marijuana, is important. Standard care includes screening for sexually transmitted diseases and thyroid disease, recommended vaccinations, routine genetic screening, a careful review of all prescription and nonprescription medications and supplements used, and a review of travel history and plans with special attention to areas known to have Zika virus, as outlined by ACOG. See Table 14.1 for additional details on elements of preconception care (15,17). Counseling on the specific risks of obesity in pregnancy and lifestyle interventions to prevent and treat obesity, including referral to a registered dietitian nutritionist (RD/RDN), is recommended when indicated.

View this table:
  • View inline
  • View popup
Table 14.1

Checklist for preconception care for women with diabetes (15,17)

Diabetes-specific counseling should include an explanation of the risks to mother and fetus related to pregnancy and the ways to reduce risk including glycemic goal setting, lifestyle management, and medical nutrition therapy. The most important diabetes-specific component of preconception care is the attainment of glycemic goals prior to conception. Diabetes-specific testing should include A1C, creatinine, and urinary albumin-to-creatinine ratio. Special attention should be paid to the review of the medication list for potentially harmful drugs (i.e., ACE inhibitors [18], angiotensin receptor blockers [18], and statins [19,20]). A referral for a comprehensive eye exam is recommended. Women with preexisting diabetic retinopathy will need close monitoring during pregnancy to assess for progression of retinopathy and provide treatment if indicated (21). The use of aspirin (81–150 mg) can be considered preconception as it is recommended for all pregnant women with diabetes (if no contraindication) by 16 weeks of gestation to reduce the risk of preeclampsia. Please see preeclampsia and aspirin for more information.

Several studies have shown improved diabetes and pregnancy outcomes when care has been delivered from preconception through pregnancy by a multidisciplinary group focused on improved glycemic control (22–25). One study showed that care of preexisting diabetes in clinics that included diabetes and obstetric specialists improved care (25). However, there is no consensus on the structure of multidisciplinary team care for diabetes and pregnancy, and there is a lack of evidence on the impact on outcomes of various methods of health care delivery (26).

GLYCEMIC TARGETS IN PREGNANCY

Recommendations

  • 14.7 Fasting and postprandial self-monitoring of blood glucose are recommended in both gestational diabetes mellitus and preexisting diabetes in pregnancy to achieve optimal glucose levels. Glucose targets are fasting plasma glucose <95 mg/dL (5.3 mmol/L) and either 1-h postprandial glucose <140 mg/dL (7.8 mmol/L) or 2-h postprandial glucose <120 mg/dL (6.7 mmol/L). Some women with preexisting diabetes should also test blood glucose preprandially. B

  • 14.8 Due to increased red blood cell turnover, A1C is slightly lower in normal pregnancy than in normal nonpregnant women. Ideally, the A1C target in pregnancy is <6% (42 mmol/mol) if this can be achieved without significant hypoglycemia, but the target may be relaxed to <7% (53 mmol/mol) if necessary to prevent hypoglycemia. B

  • 14.9 When used in addition to pre- and postprandial self-monitoring of blood glucose, continuous glucose monitoring can help to achieve A1C targets in diabetes and pregnancy. B

  • 14.10 When used in addition to self-monitoring of blood glucose targeting traditional pre- and postprandial targets, continuous glucose monitoring can reduce macrosomia and neonatal hypoglycemia in pregnancy complicated by type 1 diabetes. B

  • 14.11 Continuous glucose monitoring metrics should not be used as a substitute for self-monitoring of blood glucose to achieve optimal pre- and postprandial glycemic targets. E

  • 14.12 Commonly used estimated A1C and glucose management indicator calculations should not be used in pregnancy as estimates of A1C. C

Pregnancy in women with normal glucose metabolism is characterized by fasting levels of blood glucose that are lower than in the nonpregnant state due to insulin-independent glucose uptake by the fetus and placenta and by mild postprandial hyperglycemia and carbohydrate intolerance as a result of diabetogenic placental hormones. In patients with preexisting diabetes, glycemic targets are usually achieved through a combination of insulin administration and medical nutrition therapy. Because glycemic targets in pregnancy are stricter than in nonpregnant individuals, it is important that women with diabetes eat consistent amounts of carbohydrates to match with insulin dosage and to avoid hyperglycemia or hypoglycemia. Referral to a registered dietitian nutritionist is important in order to establish a food plan and insulin-to-carbohydrate ratio and to determine weight gain goals.

Insulin Physiology

Given that early pregnancy is a time of enhanced insulin sensitivity and lower glucose levels, many women with type 1 diabetes will have lower insulin requirements and increased risk for hypoglycemia (27). The situation rapidly reverses by approximately 16 weeks as insulin resistance increases exponentially during the second and early third trimesters to 2–3 times the preprandial requirement. The insulin requirement levels off toward the end of the third trimester with placental aging. A rapid reduction in insulin requirements can indicate the development of placental insufficiency (28). In women with normal pancreatic function, insulin production is sufficient to meet the challenge of this physiological insulin resistance and to maintain normal glucose levels. However, in women with diabetes, hyperglycemia occurs if treatment is not adjusted appropriately.

Glucose Monitoring

Reflecting this physiology, fasting and postprandial monitoring of blood glucose is recommended to achieve metabolic control in pregnant women with diabetes. Preprandial testing is also recommended when using insulin pumps or basal-bolus therapy so that premeal rapid-acting insulin dosage can be adjusted. Postprandial monitoring is associated with better glycemic control and lower risk of preeclampsia (29–31). There are no adequately powered randomized trials comparing different fasting and postmeal glycemic targets in diabetes in pregnancy.

Similar to the targets recommended by ACOG (the same as for GDM; described below) (32), the ADA-recommended targets for women with type 1 or type 2 diabetes are as follows:

  • Fasting glucose <95 mg/dL (5.3 mmol/L) and either

  • One-hour postprandial glucose <140 mg/dL (7.8 mmol/L) or

  • Two-hour postprandial glucose <120 mg/dL (6.7 mmol/L)

These values represent optimal control if they can be achieved safely. In practice, it may be challenging for women with type 1 diabetes to achieve these targets without hypoglycemia, particularly women with a history of recurrent hypoglycemia or hypoglycemia unawareness. If women cannot achieve these targets without significant hypoglycemia, the ADA suggests less-stringent targets based on clinical experience and individualization of care.

A1C in Pregnancy

In studies of women without preexisting diabetes, increasing A1C levels within the normal range are associated with adverse outcomes (33). In the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, increasing levels of glycemia were also associated with worsening outcomes (34). Observational studies in preexisting diabetes and pregnancy show the lowest rates of adverse fetal outcomes in association with A1C <6–6.5% (42–48 mmol/mol) early in gestation (4–6,35). Clinical trials have not evaluated the risks and benefits of achieving these targets, and treatment goals should account for the risk of maternal hypoglycemia in setting an individualized target of <6% (42 mmol/mol) to <7% (53 mmol/mol). Due to physiological increases in red blood cell turnover, A1C levels fall during normal pregnancy (36,37). Additionally, as A1C represents an integrated measure of glucose, it may not fully capture postprandial hyperglycemia, which drives macrosomia. Thus, although A1C may be useful, it should be used as a secondary measure of glycemic control in pregnancy, after self-monitoring of blood glucose.

In the second and third trimesters, A1C <6% (42 mmol/mol) has the lowest risk of large-for-gestational-age infants (35,38,39), preterm delivery (40), and preeclampsia (1,41). Taking all of this into account, a target of <6% (42 mmol/mol) is optimal during pregnancy if it can be achieved without significant hypoglycemia. The A1C target in a given patient should be achieved without hypoglycemia, which, in addition to the usual adverse sequelae, may increase the risk of low birth weight (42). Given the alteration in red blood cell kinetics during pregnancy and physiological changes in glycemic parameters, A1C levels may need to be monitored more frequently than usual (e.g., monthly).

Continuous Glucose Monitoring in Pregnancy

CONCEPTT (Continuous Glucose Monitoring in Pregnant Women With Type 1 Diabetes Trial) was a randomized controlled trial of continuous glucose monitoring (CGM) in addition to standard care, including optimization of pre- and postprandial glucose targets versus standard care for pregnant women with type 1 diabetes. It demonstrated the value of CGM in pregnancy complicated by type 1 diabetes by showing a mild improvement in A1C without an increase in hypoglycemia and reductions in large-for-gestational-age births, length of stay, and neonatal hypoglycemia (43). An observational cohort study that evaluated the glycemic variables reported using CGM and their association with large-for-gestational-age births found that mean glucose had a greater association than time in range, time below range, or time above range (44). Using the CGM-reported mean glucose is superior to the use of estimated A1C, glucose management indicator, and other calculations to estimate A1C given the changes to A1C that occur in pregnancy (45).

MANAGEMENT OF GESTATIONAL DIABETES MELLITUS

Recommendations

  • 14.13 Lifestyle behavior change is an essential component of management of gestational diabetes mellitus and may suffice for the treatment of many women. Insulin should be added if needed to achieve glycemic targets. A

  • 14.14 Insulin is the preferred medication for treating hyperglycemia in gestational diabetes mellitus. Metformin and glyburide should not be used as first-line agents, as both cross the placenta to the fetus. A Other oral and noninsulin injectable glucose-lowering medications lack long-term safety data.

  • 14.15 Metformin, when used to treat polycystic ovary syndrome and induce ovulation, should be discontinued by the end of the first trimester. A

GDM is characterized by increased risk of macrosomia and birth complications and an increased risk of maternal type 2 diabetes after pregnancy. The association of macrosomia and birth complications with oral glucose tolerance test (OGTT) results is continuous with no clear inflection points (34). In other words, risks increase with progressive hyperglycemia. Therefore, all women should be tested as outlined in Section 2 “Classification and Diagnosis of Diabetes” (https://doi.org/10.2337/dc20-S002). Although there is some heterogeneity, many randomized controlled trials (RCTs) suggest that the risk of GDM may be reduced by diet, exercise, and lifestyle counseling, particularly when interventions are started during the first or early in the second trimester (46–48).

Lifestyle Management

After diagnosis, treatment starts with medical nutrition therapy, physical activity, and weight management depending on pregestational weight, as outlined in the section below on preexisting type 2 diabetes, and glucose monitoring aiming for the targets recommended by the Fifth International Workshop-Conference on Gestational Diabetes Mellitus (48):

  • Fasting glucose <95 mg/dL (5.3 mmol/L) and either

  • One-hour postprandial glucose <140 mg/dL (7.8 mmol/L) or

  • Two-hour postprandial glucose <120 mg/dL (6.7 mmol/L)

Depending on the population, studies suggest that 70–85% of women diagnosed with GDM under Carpenter-Coustan can control GDM with lifestyle modification alone; it is anticipated that this proportion will be even higher if the lower International Association of Diabetes and Pregnancy Study Groups (49) diagnostic thresholds are used.

Medical Nutrition Therapy

Medical nutrition therapy for GDM is an individualized nutrition plan developed between the woman and an RD/RDN familiar with the management of GDM (50,51). The food plan should provide adequate calorie intake to promote fetal/neonatal and maternal health, achieve glycemic goals, and promote weight gain according to 2009 Institute of Medicine recommendations (52). There is no definitive research that identifies a specific optimal calorie intake for women with GDM or suggests that their calorie needs are different from those of pregnant women without GDM. The food plan should be based on a nutrition assessment with guidance from the Dietary Reference Intakes (DRI). The DRI for all pregnant women recommends a minimum of 175 g of carbohydrate, a minimum of 71 g of protein, and 28 g of fiber. The diet should not be high in saturated fat. As is true for all nutrition therapy in patients with diabetes, the amount and type of carbohydrate will impact glucose levels. Simple carbohydrates will result in higher postmeal excursions.

Pharmacologic Therapy

Treatment of GDM with lifestyle and insulin has been demonstrated to improve perinatal outcomes in two large randomized studies as summarized in a U.S. Preventive Services Task Force review (53). Insulin is the first-line agent recommended for treatment of GDM in the U.S. While individual RCTs support limited efficacy of metformin (54,55) and glyburide (56) in reducing glucose levels for the treatment of GDM, these agents are not recommended as first-line treatment for GDM because they are known to cross the placenta and data on long-term safety for offspring is of some concern (32). Furthermore, glyburide and metformin failed to provide adequate glycemic control in separate randomized controlled trials, failing in 23% and 25–28% of women with GDM, respectively (57,58).

Sulfonylureas

Sulfonylureas are known to cross the placenta and have been associated with increased neonatal hypoglycemia. Concentrations of glyburide in umbilical cord plasma are approximately 50–70% of maternal levels (57,58). Glyburide was associated with a higher rate of neonatal hypoglycemia and macrosomia than insulin or metformin in a 2015 meta-analysis and systematic review (59). More recently, glyburide failed to be found noninferior to insulin based on a composite outcome of neonatal hypoglycemia, macrosomia, and hyperbilirubinemia (60). Long-term safety data for offspring exposed to glyburide are not available (60).

Metformin

Metformin was associated with a lower risk of neonatal hypoglycemia and less maternal weight gain than insulin in systematic reviews (59,61,62,65). However, metformin readily crosses the placenta, resulting in umbilical cord blood levels of metformin as high or higher than simultaneous maternal levels (66,67). In the Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU) study’s analyses of 7- to 9-year-old offspring, the 9-year-old offspring exposed to metformin in the Auckland cohort for the treatment of GDM were heavier and had a higher waist-to-height ratio and waist circumference than those exposed to insulin (68). This was not found in the Adelaide cohort. In two RCTs of metformin use in pregnancy for polycystic ovary syndrome, follow-up of 4-year-old offspring demonstrated higher BMI and increased obesity in the offspring exposed to metformin (69,70). A follow-up study at 5–10 years showed that the offspring had higher BMI, weight-to-height ratios, waist circumferences, and a borderline increase in fat mass (70,71). Metformin is being studied in two ongoing trials in type 2 diabetes (Metformin in Women with Type 2 Diabetes in Pregnancy Trial [MiTY] [72] and Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy [MOMPOD] [73]), but long-term offspring data will not be available for some time. A recent meta-analysis concluded that metformin exposure resulted in smaller neonates with acceleration of postnatal growth resulting in higher BMI in childhood (68,69).

Randomized, double-blind, controlled trials comparing metformin with other therapies for ovulation induction in women with polycystic ovary syndrome have not demonstrated benefit in preventing spontaneous abortion or GDM (74), and there is no evidence-based need to continue metformin in such patients (75–77).

There are some women with GDM requiring medical therapy who, due to cost, language barriers, comprehension, or cultural influences, may not be able to use insulin safely or effectively in pregnancy. Oral agents may be an alternative in these women after a discussion of the known risks and the need for more long-term safety data in offspring. However, due to the potential for growth restriction or acidosis in the setting of placental insufficiency, metformin should not be used in women with hypertension, preeclampsia, or at risk for intrauterine growth restriction (78,79).

Insulin

Insulin use should follow the guidelines below. Both multiple daily insulin injections and continuous subcutaneous insulin infusion are reasonable delivery strategies, and neither has been shown to be superior to the other during pregnancy (80).

MANAGEMENT OF PREEXISTING TYPE 1 DIABETES AND TYPE 2 DIABETES IN PREGNANCY

Insulin Use

Recommendations

  • 14.16 Insulin is the preferred agent for management of both type 1 diabetes and type 2 diabetes in pregnancy. E

  • 14.17 Either multiple daily injections or insulin pump technology can be used in pregnancy complicated by type 1 diabetes. C

The physiology of pregnancy necessitates frequent titration of insulin to match changing requirements and underscores the importance of daily and frequent self-monitoring of blood glucose. Due to the complexity of insulin management in pregnancy, referral to a specialized center offering team-based care (with team members including maternal-fetal medicine specialist, endocrinologist, or other provider experienced in managing pregnancy in women with preexisting diabetes, dietitian, nurse, and social worker, as needed) is recommended if this resource is available.

None of the currently available human insulin preparations have been demonstrated to cross the placenta (80–86). A recent Cochrane systematic review was not able to recommend any specific insulin regimen over another for the treatment of diabetes in pregnancy (87).

While many providers prefer insulin pumps in pregnancy, it is not clear that they are superior to multiple daily injections (88–90). Closed-loop technology that is U.S. Food and Drug Administration approved outside of pregnancy can only target a glucose of 120 mg/dL at this time, which is likely to be too high for optimal nocturnal control in pregnancy. However, given potential benefits, ongoing work is being done in this area.

Type 1 Diabetes

Women with type 1 diabetes have an increased risk of hypoglycemia in the first trimester and, like all women, have altered counterregulatory response in pregnancy that may decrease hypoglycemia awareness. Education for patients and family members about the prevention, recognition, and treatment of hypoglycemia is important before, during, and after pregnancy to help to prevent and manage the risks of hypoglycemia. Insulin resistance drops rapidly with delivery of the placenta.

Pregnancy is a ketogenic state, and women with type 1 diabetes, and to a lesser extent those with type 2 diabetes, are at risk for diabetic ketoacidosis (DKA) at lower blood glucose levels than in the nonpregnant state. Women with type 1 diabetes should be prescribed ketone strips and receive education on diabetic ketoacidosis prevention and detection. DKA carries a high risk of stillbirth. Women in DKA who are unable to eat often require 10% dextrose with an insulin drip to adequately meet the higher carbohydrate demands of the placenta and fetus in the third trimester in order to resolve their ketosis.

Retinopathy is a special concern in pregnancy. Rapid implementation of euglycemia in the setting of retinopathy is associated with worsening of retinopathy (21).

Type 2 Diabetes

Type 2 diabetes is often associated with obesity. Recommended weight gain during pregnancy for overweight women is 15–25 lb and for obese women is 10–20 lb (52). There is no adequate data on optimal weight gain versus weight maintenance in women with a BMI >35 kg/m2.

Glycemic control is often easier to achieve in women with type 2 diabetes than in those with type 1 diabetes but can require much higher doses of insulin, sometimes necessitating concentrated insulin formulations. As in type 1 diabetes, insulin requirements drop dramatically after delivery.

The risk for associated hypertension and other comorbidities may be as high or higher with type 2 diabetes as with type 1 diabetes, even if diabetes is better controlled and of shorter apparent duration, with pregnancy loss appearing to be more prevalent in the third trimester in women with type 2 diabetes compared with the first trimester in women with type 1 diabetes (91,92).

PREECLAMPSIA AND ASPIRIN

Recommendation

  • 14.18 Women with type 1 or type 2 diabetes should be prescribed low-dose aspirin 60–150 mg/day (usual dose 81 mg/day) by the end of the first trimester in order to lower the risk of preeclampsia. A

Diabetes in pregnancy is associated with an increased risk of preeclampsia (93). Based upon the results of clinical trials and meta-analyses (94), the U.S. Preventive Services Task Force recommends the use of low-dose aspirin (81 mg/day) as a preventive medication at 12 weeks of gestation in women who are at high risk for preeclampsia (95). A cost-benefit analysis has concluded that this approach would reduce morbidity, save lives, and lower health care costs (96). However, more study is needed to assess the long-term effects of prenatal aspirin exposure on offspring (97).

PREGNANCY AND DRUG CONSIDERATIONS

Recommendations

  • 14.19 In pregnant patients with diabetes and hypertension or significant proteinuria, a consistent blood pressure >135/85 mmHg should be treated in the interest of optimizing long-term maternal health. Blood pressure targets should range no lower than 120/80 mmHg, as lower blood pressure targets may impair fetal growth. C

  • 14.20 Potentially harmful medications in pregnancy (i.e., ACE inhibitors, angiotensin receptor blockers, statins) should be stopped at conception and avoided in sexually active women of childbearing age who are not using reliable contraception. B

In normal pregnancy, blood pressure is lower than in the nonpregnant state. In a pregnancy complicated by diabetes and chronic hypertension, a target goal blood pressure of <135/85 mmHg is reasonable (98,99). Blood pressure targets lower than 120/80 mmHg may be associated with impaired fetal growth, especially in the setting of placental insufficiency. In a 2015 study targeting diastolic blood pressure of 100 mmHg versus 85 mmHg in pregnant women, only 6% of whom had GDM at enrollment, there was no difference in pregnancy loss, neonatal care, or other neonatal outcomes, although women in the less intensive treatment group had a higher rate of uncontrolled hypertension (100).

During pregnancy, treatment with ACE inhibitors and angiotensin receptor blockers is contraindicated because they may cause fetal renal dysplasia, oligohydramnios, pulmonary hypoplasia, and intrauterine growth restriction (18). Antihypertensive drugs known to be effective and safe in pregnancy include methyldopa, nifedipine, labetalol, diltiazem, clonidine, and prazosin. Atenolol is not recommended, but other β-blockers may be used, if necessary. Chronic diuretic use during pregnancy is not recommended as it has been associated with restricted maternal plasma volume, which may reduce uteroplacental perfusion (101). On the basis of available evidence, statins should also be avoided in pregnancy (102).

See pregnancy and antihypertensive medications in Section 10 “Cardiovascular Disease and Risk Management” (https://doi.org/10.2337/dc20-s010) for more information on managing blood pressure in pregnancy.

POSTPARTUM CARE

Recommendations

  • 14.21 Insulin resistance decreases dramatically immediately postpartum, and insulin requirements need to be evaluated and adjusted as they are often roughly half the prepregnancy requirements for the initial few days postpartum. C

  • 14.22 A contraceptive plan should be discussed and implemented with all women with diabetes of reproductive potential. C

  • 14.23 Screen women with a recent history of gestational diabetes mellitus at 4–12 weeks postpartum, using the 75-g oral glucose tolerance test and clinically appropriate nonpregnancy diagnostic criteria. B

  • 14.24 Women with a history of gestational diabetes mellitus found to have prediabetes should receive intensive lifestyle interventions and/or metformin to prevent diabetes. A

  • 14.25 Women with a history of gestational diabetes mellitus should have lifelong screening for the development of type 2 diabetes or prediabetes at least every 3 years. B

  • 14.26 Women with a history of gestational diabetes mellitus should seek preconception screening for diabetes and preconception care to identify and treat hyperglycemia and prevent congenital malformations. E

  • 14.27 Postpartum care should include psychosocial assessment and support for self-care. E

Gestational Diabetes Mellitus

Initial Testing

Because GDM often represents previously undiagnosed prediabetes, type 2 diabetes, maturity-onset diabetes of the young, or even developing type 1 diabetes, women with GDM should be tested for persistent diabetes or prediabetes at 4–12 weeks postpartum with a 75-g OGTT using nonpregnancy criteria as outlined in Section 2 “Classification and Diagnosis of Diabetes” (https://doi.org/10.2334/dc20-S002).

Postpartum Follow-up

The OGTT is recommended over A1C at 4–12 weeks postpartum because A1C may be persistently impacted (lowered) by the increased red blood cell turnover related to pregnancy, by blood loss at delivery, or by the preceding 3-month glucose profile. The OGTT is more sensitive at detecting glucose intolerance, including both prediabetes and diabetes. Women of reproductive age with prediabetes may develop type 2 diabetes by the time of their next pregnancy and will need preconception evaluation. Because GDM is associated with an increased lifetime maternal risk for diabetes estimated at 50–70% after 15–25 years (103,104), women should also be tested every 1–3 years thereafter if the 4–12 weeks postpartum 75-g OGTT is normal. Ongoing evaluation may be performed with any recommended glycemic test (e.g., annual A1C, annual fasting plasma glucose, or triennial 75-g OGTT using nonpregnant thresholds).

Gestational Diabetes Mellitus and Type 2 Diabetes

Women with a history of GDM have a greatly increased risk of conversion to type 2 diabetes over time (103). In the prospective Nurses’ Health Study II (NHS II), subsequent diabetes risk after a history of GDM was significantly lower in women who followed healthy eating patterns (105). Adjusting for BMI moderately, but not completely, attenuated this association. Interpregnancy or postpartum weight gain is associated with increased risk of adverse pregnancy outcomes in subsequent pregnancies (106) and earlier progression to type 2 diabetes.

Both metformin and intensive lifestyle intervention prevent or delay progression to diabetes in women with prediabetes and a history of GDM. Of women with a history of GDM and prediabetes, only 5–6 women need to be treated with either intervention to prevent one case of diabetes over 3 years (107). In these women, lifestyle intervention and metformin reduced progression to diabetes by 35% and 40%, respectively, over 10 years compared with placebo (108). If the pregnancy has motivated the adoption of a healthier diet, building on these gains to support weight loss is recommended in the postpartum period.

Preexisting Type 1 and Type 2 Diabetes

Insulin sensitivity increases dramatically with delivery of the placenta. In one study, insulin requirements in the immediate postpartum period are roughly 34% lower than prepregnancy insulin requirements (109,110). Insulin sensitivity then returns to prepregnancy levels over the following 1–2 weeks. In women taking insulin, particular attention should be directed to hypoglycemia prevention in the setting of breastfeeding and erratic sleep and eating schedules (111).

Lactation

In light of the immediate nutritional and immunological benefits of breastfeeding for the baby, all women including those with diabetes should be supported in attempts to breastfeed. Breastfeeding may also confer longer-term metabolic benefits to both mother (112) and offspring (113) However, lactation can increase the risk of overnight hypoglycemia, and insulin dosing may need to be adjusted.

Contraception

A major barrier to effective preconception care is the fact that the majority of pregnancies are unplanned. Planning pregnancy is critical in women with preexisting diabetes due to the need for preconception glycemic control to prevent congenital malformations and reduce the risk of other complications. Therefore, all women with diabetes of childbearing potential should have family planning options reviewed at regular intervals to make sure that effective contraception is implemented and maintained. This applies to women in the immediate postpartum period. Women with diabetes have the same contraception options and recommendations as those without diabetes. Long-acting, reversable contraception may be ideal for many women. The risk of an unplanned pregnancy outweighs the risk of any given contraception option.

Footnotes

  • Suggested citation: American Diabetes Association. 14. Management of diabetes in pregnancy: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S183-S192

  • © 2019 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Dabelea D,
    2. Hanson RL,
    3. Lindsay RS, et al
    . Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes 2000;49:2208–2211
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Holmes VA,
    2. Young IS,
    3. Patterson CC, et al.; Diabetes and Pre-eclampsia Intervention Trial Study Group
    . Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the Diabetes and Pre-eclampsia Intervention Trial. Diabetes Care 2011;34:1683–1688
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Guerin A,
    2. Nisenbaum R,
    3. Ray JG
    . Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care 2007;30:1920–1925
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Jensen DM,
    2. Korsholm L,
    3. Ovesen P, et al
    . Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care 2009;32:1046–1048
    OpenUrlAbstract/FREE Full Text
    1. Nielsen GL,
    2. Møller M,
    3. Sørensen HT
    . HbA1c in early diabetic pregnancy and pregnancy outcomes: a Danish population-based cohort study of 573 pregnancies in women with type 1 diabetes. Diabetes Care 2006;29:2612–2616
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Suhonen L,
    2. Hiilesmaa V,
    3. Teramo K
    . Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus. Diabetologia 2000;43:79–82
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Charron-Prochownik D,
    2. Sereika SM,
    3. Becker D, et al
    . Long-term effects of the booster-enhanced READY-Girls preconception counseling program on intentions and behaviors for family planning in teens with diabetes. Diabetes Care 2013;36:3870–3874
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Peterson C,
    2. Grosse SD,
    3. Li R, et al
    . Preventable health and cost burden of adverse birth outcomes associated with pregestational diabetes in the United States. Am J Obstet Gynecol 2015;212:74.e1–74.e9
    OpenUrlCrossRef
  8. ↵
    1. Britton LE,
    2. Hussey JM,
    3. Berry DC,
    4. Crandell JL,
    5. Brooks JL,
    6. Bryant AG
    . Contraceptive use among women with prediabetes and diabetes in a US national sample. J Midwifery Womens Health 2019;64:36–45
    OpenUrl
    1. Morris JR,
    2. Tepper NK
    . Description and comparison of postpartum use of effective contraception among women with and without diabetes. Contraception. 1 September 2019 [Epub ahead of print]. DOI: 10.1016/j.contraception.2019.08.008
    1. Goldstuck ND,
    2. Steyn PS
    . The intrauterine device in women with diabetes mellitus type I and II: a systematic review. ISRN Obstet Gynecol 2013. Accessed 3 October 2019. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874344/
    1. Wu JP,
    2. Moniz MH,
    3. Ursu AN
    . Long-acting reversible contraception-highly efficacious, safe, and underutilized. JAMA 2018;320:397–398
  9. ↵
    ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus. Obstet Gynecol 2018;132:e228–e248
    OpenUrl
  10. ↵
    1. Charron-Prochownik D,
    2. Downs J
    . Diabetes and Reproductive Health for Girls. Alexandria, VA, American Diabetes Association, 2016
  11. ↵
    ACOG Committee Opinion No. 762: Prepregnancy Counseling. Obstet Gynecol 2019;133:e78–e89
    OpenUrl
  12. ↵
    1. Alexander EK,
    2. Pearce EN,
    3. Brent GA, et al
    . 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 2017;27:315–389
    OpenUrlCrossRefPubMed
  13. ↵
    1. Ramos DE
    . Preconception health: changing the paradigm on well-woman health. Obstet Gynecol Clin North Am 2019;46:399–408
    OpenUrl
  14. ↵
    1. Bullo M,
    2. Tschumi S,
    3. Bucher BS,
    4. Bianchetti MG,
    5. Simonetti GD
    . Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 2012;60:444–450
    OpenUrlCrossRefPubMed
  15. ↵
    1. Taguchi N,
    2. Rubin ET,
    3. Hosokawa A, et al
    . Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol 2008;26:175–177
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Bateman BT,
    2. Hernandez-Diaz S,
    3. Fischer MA, et al
    . Statins and congenital malformations: cohort study. BMJ 2015;350:h1035
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Chew EY,
    2. Mills JL,
    3. Metzger BE, et al
    .; National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Metabolic control and progression of retinopathy: the Diabetes in Early Pregnancy Study. Diabetes Care 1995;18:631–637
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. McElvy SS,
    2. Miodovnik M,
    3. Rosenn B, et al
    . A focused preconceptional and early pregnancy program in women with type 1 diabetes reduces perinatal mortality and malformation rates to general population levels. J Matern Fetal Med 2000;9:14–20
    OpenUrlCrossRefPubMed
    1. Murphy HR,
    2. Roland JM,
    3. Skinner TC, et al
    . Effectiveness of a regional prepregnancy care program in women with type 1 and type 2 diabetes: benefits beyond glycemic control. Diabetes Care 2010;33:2514–2520
    OpenUrlAbstract/FREE Full Text
    1. Elixhauser A,
    2. Weschler JM,
    3. Kitzmiller JL, et al
    . Cost-benefit analysis of preconception care for women with established diabetes mellitus. Diabetes Care 1993;16:1146–1157
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Owens LA,
    2. Avalos G,
    3. Kirwan B,
    4. Carmody L,
    5. Dunne F
    . ATLANTIC DIP: closing the loop: a change in clinical practice can improve outcomes for women with pregestational diabetes. Diabetes Care 2012;35:1669–1671
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Taylor C,
    2. McCance DR,
    3. Chappell L,
    4. Nelson-Piercy C,
    5. Thorne SA,
    6. Ismail KMK, et al
    . Implementation of guidelines for multidisciplinary team management of pregnancy in women with pre-existing diabetes or cardiac conditions: results from a UK national survey. BMC Pregnancy Childbirth 2017;17:434
  21. ↵
    1. García-Patterson A,
    2. Gich I,
    3. Amini SB,
    4. Catalano PM,
    5. de Leiva A,
    6. Corcoy R
    . Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction. Diabetologia 2010;53:446–451
    OpenUrlCrossRefPubMed
  22. ↵
    1. Padmanabhan S,
    2. Lee VW,
    3. Mclean M, et al
    . The association of falling insulin requirements with maternal biomarkers and placental dysfunction: a prospective study of women with preexisting diabetes in pregnancy. Diabetes Care 2017;40:1323–1330
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Manderson JG,
    2. Patterson CC,
    3. Hadden DR,
    4. Traub AI,
    5. Ennis C,
    6. McCance DR
    . Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial. Am J Obstet Gynecol 2003;189:507–512
    OpenUrlCrossRefPubMedWeb of Science
    1. de Veciana M,
    2. Major CA,
    3. Morgan MA, et al
    . Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995;333:1237–1241
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Jovanovic-Peterson L,
    2. Peterson CM,
    3. Reed GF, et al
    . Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development--Diabetes in Early Pregnancy Study. Am J Obstet Gynecol 1991;164:103–111
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    ACOG Practice Bulletin No. 190: Gestational Diabetes. Obstet Gynecol 2018;131:e49–e64
    OpenUrlCrossRefPubMed
  26. ↵
    1. Ho Y-R,
    2. Wang P,
    3. Lu M-C,
    4. Tseng S-T,
    5. Yang C-P,
    6. Yan Y-H
    . Associations of mid-pregnancy HbA1c with gestational diabetes and risk of adverse pregnancy outcomes in high-risk Taiwanese women. PLoS One 2017;12:e0177563
    OpenUrl
  27. ↵
    1. Metzger BE,
    2. Lowe LP,
    3. Dyer AR, et al
    .; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991–2002
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Maresh MJA,
    2. Holmes VA,
    3. Patterson CC, et al.; Diabetes and Pre-eclampsia Intervention Trial Study Group
    . Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes. Diabetes Care 2015;38:34–42
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Nielsen LR,
    2. Ekbom P,
    3. Damm P, et al
    . HbA1c levels are significantly lower in early and late pregnancy. Diabetes Care 2004;27:1200–1201
    OpenUrlFREE Full Text
  30. ↵
    1. Mosca A,
    2. Paleari R,
    3. Dalfrà MG, et al
    . Reference intervals for hemoglobin A1c in pregnant women: data from an Italian multicenter study. Clin Chem 2006;52:1138–1143
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Hummel M,
    2. Marienfeld S,
    3. Huppmann M, et al
    . Fetal growth is increased by maternal type 1 diabetes and HLA DR4-related gene interactions. Diabetologia 2007;50:850–858
    OpenUrlPubMed
  32. ↵
    1. Cyganek K,
    2. Skupien J,
    3. Katra B, et al
    . Risk of macrosomia remains glucose-dependent in a cohort of women with pregestational type 1 diabetes and good glycemic control. Endocrine 2017;55:447–455
    OpenUrlPubMed
  33. ↵
    1. Abell SK,
    2. Boyle JA,
    3. de Courten B, et al
    . Impact of type 2 diabetes, obesity and glycaemic control on pregnancy outcomes. Aust N Z J Obstet Gynaecol 2017;57:308–314
    OpenUrlPubMed
  34. ↵
    1. Temple RC,
    2. Aldridge V,
    3. Stanley K,
    4. Murphy HR
    . Glycaemic control throughout pregnancy and risk of pre-eclampsia in women with type I diabetes. BJOG 2006;113:1329–1332
    OpenUrlCrossRefPubMed
  35. ↵
    1. Combs CA,
    2. Gunderson E,
    3. Kitzmiller JL,
    4. Gavin LA,
    5. Main EK
    . Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy. Diabetes Care 1992;15:1251–1257
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Feig DS,
    2. Donovan LE,
    3. Corcoy R, et al.; CONCEPTT Collaborative Group
    . Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet 2017;390:2347–2359
    OpenUrlCrossRefPubMed
  37. ↵
    1. Kristensen K,
    2. Ögge LE,
    3. Sengpiel V, et al
    . Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies. Diabetologia 2019;62:1143–1153
    OpenUrl
  38. ↵
    1. Law GR,
    2. Gilthorpe MS,
    3. Secher AL, et al
    . Translating HbA1c measurements into estimated average glucose values in pregnant women with diabetes. Diabetologia 2017;60:618–624
    OpenUrl
  39. ↵
    1. Koivusalo SB,
    2. Rönö K,
    3. Klemetti MM, et al
    . Gestational diabetes mellitus can be prevented by lifestyle intervention: the Finnish Gestational Diabetes Prevention Study (RADIEL): a randomized controlled trial. Diabetes Care 2016;39:24–30
    OpenUrlAbstract/FREE Full Text
    1. Wang C,
    2. Wei Y,
    3. Zhang X, et al
    . A randomized clinical trial of exercise during pregnancy to prevent gestational diabetes mellitus and improve pregnancy outcome in overweight and obese pregnant women. Am J Obstet Gynecol 2017;216:340–351
    OpenUrl
  40. ↵
    1. Metzger BE,
    2. Buchanan TA,
    3. Coustan DR, et al
    . Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care;2007;30(Suppl._2):S251–S260
  41. ↵
    1. Mayo K,
    2. Melamed N,
    3. Vandenberghe H,
    4. Berger H
    . The impact of adoption of the international association of diabetes in pregnancy study group criteria for the screening and diagnosis of gestational diabetes. Am J Obstet Gynecol 2015;212:224.e1–224.e9
    OpenUrlCrossRef
  42. ↵
    1. Han S,
    2. Crowther CA,
    3. Middleton P,
    4. Heatley E
    . Different types of dietary advice for women with gestational diabetes mellitus. Cochrane Database Syst Rev 2013;3:CD009275
  43. ↵
    1. Viana LV,
    2. Gross JL,
    3. Azevedo MJ
    . Dietary intervention in patients with gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials on maternal and newborn outcomes. Diabetes Care 2014;37:3345–3355
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Institute of Medicine and National Research Council. Weight Gain During Pregnancy: Reexamining the Guidelines. Washington, D.C., National Academies Press, 2009
  45. ↵
    1. Hartling L,
    2. Dryden DM,
    3. Guthrie A,
    4. Muise M,
    5. Vandermeer B,
    6. Donovan L
    . Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. Ann Intern Med 2013;159:123–129
    OpenUrlCrossRefPubMedWeb of Science
  46. ↵
    1. Rowan JA,
    2. Hague WM,
    3. Gao W,
    4. Battin MR,
    5. Moore MP; MiG Trial Investigators
    . Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008;358:2003–2015
    OpenUrlCrossRefPubMedWeb of Science
  47. ↵
    1. Gui J,
    2. Liu Q,
    3. Feng L
    . Metformin vs insulin in the management of gestational diabetes: a meta-analysis. PLoS One 2013;8:e64585
    OpenUrlCrossRefPubMed
  48. ↵
    1. Langer O,
    2. Conway DL,
    3. Berkus MD,
    4. Xenakis EM-J,
    5. Gonzales O
    . A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000;343:1134–1138
    OpenUrlCrossRefPubMedWeb of Science
  49. ↵
    1. Hebert MF,
    2. Ma X,
    3. Naraharisetti SB, et al.; Obstetric-Fetal Pharmacology Research Unit Network
    . Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther 2009;85:607–614
    OpenUrlCrossRefPubMedWeb of Science
  50. ↵
    1. Malek R,
    2. Davis SN
    . Pharmacokinetics, efficacy and safety of glyburide for treatment of gestational diabetes mellitus. Expert Opin Drug Metab Toxicol 2016;12:691–699
    OpenUrlCrossRefPubMed
  51. ↵
    1. Balsells M,
    2. García-Patterson A,
    3. Solà I,
    4. Roqué M,
    5. Gich I,
    6. Corcoy R
    . Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ 2015;350:h102
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Sénat M-V,
    2. Affres H,
    3. Letourneau A, et al.; Groupe de Recherche en Obstétrique et Gynécologie (GROG)
    . Effect of glyburide vs subcutaneous insulin on perinatal complications among women with gestational diabetes: a randomized clinical trial. JAMA 2018;319:1773–1780
    OpenUrlPubMed
  53. ↵
    1. Silva JC,
    2. Pacheco C,
    3. Bizato J,
    4. de Souza BV,
    5. Ribeiro TE,
    6. Bertini AM
    . Metformin compared with glyburide for the management of gestational diabetes. Int J Gynaecol Obstet 2010;111:37–40
    OpenUrlCrossRefPubMed
  54. ↵
    1. Nachum Z,
    2. Zafran N,
    3. Salim R, et al
    . Glyburide versus metformin and their combination for the treatment of gestational diabetes mellitus: a randomized controlled study. Diabetes Care 2017;40:332–337
    OpenUrlAbstract/FREE Full Text
  55. Reference removed during proofreading.
  56. Reference removed during proofreading.
  57. ↵
    1. Jiang Y-F,
    2. Chen X-Y,
    3. Ding T,
    4. Wang X-F,
    5. Zhu Z-N,
    6. Su S-W
    . Comparative efficacy and safety of OADs in management of GDM: network meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2015;100:2071–2080
    OpenUrlCrossRefPubMed
  58. ↵
    1. Vanky E,
    2. Zahlsen K,
    3. Spigset O,
    4. Carlsen SM
    . Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril 2005;83:1575–1578
    OpenUrlCrossRefPubMedWeb of Science
  59. ↵
    1. Charles B,
    2. Norris R,
    3. Xiao X,
    4. Hague W
    . Population pharmacokinetics of metformin in late pregnancy. Ther Drug Monit 2006;28:67–72
    OpenUrlCrossRefPubMedWeb of Science
  60. ↵
    1. Rowan JA,
    2. Rush EC,
    3. Plank LD, et al
    . Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. BMJ Open Diabetes Res Care 2018;6:e000456
    OpenUrlPubMed
  61. ↵
    1. Hanem LGE,
    2. Stridsklev S,
    3. Júlíusson PB, et al
    . Metformin use in PCOS pregnancies increases the risk of offspring overweight at 4 years of age: follow-up of two RCTs. J Clin Endocrinol Metab 2018;103:1612–1621
    OpenUrlPubMed
  62. ↵
    1. Tarry-Adkins JL,
    2. Aiken CE,
    3. Ozanne SE
    . Neonatal, infant, and childhood growth following metformin versus insulin treatment for gestational diabetes: a systematic review and meta-analysis. PLoS Med 2019;16:e1002848
    OpenUrl
  63. ↵
    1. Hanem LGE,
    2. Salvesen Ø,
    3. Juliusson PB, et al
    . Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5-10 year follow-up of the PregMet randomised controlled trial. Lancet Child Adolesc Health 2019;3:166–174
    OpenUrl
  64. ↵
    Mount Sinai Hospital, Canada. Metformin in Women With Type 2 Diabetes in Pregnancy Trial (MiTy). In: ClinicalTrials.gov. Bethesda, MD, National Library of Medicine, 2019. Accessed 3 October 2019. Available from https://clinicaltrials.gov/ct2/show/NCT01353391
  65. ↵
    University of North Carolina, Chapel Hill. Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD). In: ClinicalTrials.gov. Bethesda, MD, National Library of Medicine, 2019. Accessed 3 October 2019. Available from https://clinicaltrials.gov/ct2/show/NCT02932475
  66. ↵
    1. Vanky E,
    2. Stridsklev S,
    3. Heimstad R, et al
    . Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab 2010;95:E448–E455
    OpenUrlCrossRefPubMedWeb of Science
  67. ↵
    1. Legro RS,
    2. Barnhart HX,
    3. Schlaff WD, et al.; Cooperative Multicenter Reproductive Medicine Network
    . Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356:551–566
    OpenUrlCrossRefPubMedWeb of Science
    1. Palomba S,
    2. Orio F Jr,
    3. Falbo A, et al
    . Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:4068–4074
    OpenUrlCrossRefPubMedWeb of Science
  68. ↵
    1. Palomba S,
    2. Orio F Jr,
    3. Nardo LG, et al
    . Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 2004;89:4801–4809
    OpenUrlCrossRefPubMedWeb of Science
  69. ↵
    1. Barbour LA,
    2. Scifres C,
    3. Valent AM, et al
    . A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes. Am J Obstet Gynecol 2018;219:367.e1–367.e7
    OpenUrlPubMed
  70. ↵
    1. Barbour LA,
    2. Feig DS
    . Metformin for gestational diabetes mellitus: progeny, perspective, and a personalized approach. Diabetes Care 2019;42:396–399
    OpenUrlFREE Full Text
  71. ↵
    1. Farrar D,
    2. Tuffnell DJ,
    3. West J,
    4. West HM
    . Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev 2016;6:CD005542
  72. Reference removed during proofreading.
    1. Pollex EK,
    2. Feig DS,
    3. Lubetsky A,
    4. Yip PM,
    5. Koren G
    . Insulin glargine safety in pregnancy: a transplacental transfer study. Diabetes Care 2010;33:29–33
    OpenUrlAbstract/FREE Full Text
    1. Holcberg G,
    2. Tsadkin-Tamir M,
    3. Sapir O, et al
    . Transfer of insulin lispro across the human placenta. Eur J Obstet Gynecol Reprod Biol 2004;115:117–118
    OpenUrlPubMed
    1. Boskovic R,
    2. Feig DS,
    3. Derewlany L,
    4. Knie B,
    5. Portnoi G,
    6. Koren G
    . Transfer of insulin lispro across the human placenta: in vitro perfusion studies. Diabetes Care 2003;26:1390–1394
    OpenUrlAbstract/FREE Full Text
    1. McCance DR,
    2. Damm P,
    3. Mathiesen ER, et al
    . Evaluation of insulin antibodies and placental transfer of insulin aspart in pregnant women with type 1 diabetes mellitus. Diabetologia 2008;51:2141–2143
    OpenUrlCrossRefPubMedWeb of Science
  73. ↵
    1. Suffecool K,
    2. Rosenn B,
    3. Niederkofler EE, et al
    . Insulin detemir does not cross the human placenta. Diabetes Care 2015;38:e20–e21
    OpenUrlFREE Full Text
  74. ↵
    1. O’Neill SM,
    2. Kenny LC,
    3. Khashan AS,
    4. West HM,
    5. Smyth RM,
    6. Kearney PM
    . Different insulin types and regimens for pregnant women with pre-existing diabetes. Cochrane Database Syst Rev 2017;2:CD011880
  75. ↵
    1. Carta Q,
    2. Meriggi E,
    3. Trossarelli GF, et al
    . Continuous subcutaneous insulin infusion versus intensive conventional insulin therapy in type I and type II diabetic pregnancy. Diabete Metab 1986;12:121–129
    OpenUrlPubMedWeb of Science
    1. Kernaghan D,
    2. Farrell T,
    3. Hammond P,
    4. Owen P
    . Fetal growth in women managed with insulin pump therapy compared to conventional insulin. Eur J Obstet Gynecol Reprod Biol 2008;137:47–49
    OpenUrlPubMed
  76. ↵
    1. Feig DS,
    2. Corcoy R,
    3. Donovan LE, et al.; CONCEPTT Collaborative Group
    . Pumps or multiple daily injections in pregnancy involving type 1 diabetes: a prespecified analysis of the CONCEPTT randomized trial. Diabetes Care 2018;41:2471–2479
    OpenUrlAbstract/FREE Full Text
  77. ↵
    1. Clausen TD,
    2. Mathiesen E,
    3. Ekbom P,
    4. Hellmuth E,
    5. Mandrup-Poulsen T,
    6. Damm P
    . Poor pregnancy outcome in women with type 2 diabetes. Diabetes Care 2005;28:323–328
    OpenUrlAbstract/FREE Full Text
  78. ↵
    1. Cundy T,
    2. Gamble G,
    3. Neale L, et al
    . Differing causes of pregnancy loss in type 1 and type 2 diabetes. Diabetes Care 2007;30:2603–2607
    OpenUrlAbstract/FREE Full Text
  79. ↵
    1. Duckitt K,
    2. Harrington D
    . Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330:565
    OpenUrlAbstract/FREE Full Text
  80. ↵
    1. Roberge S,
    2. Bujold E,
    3. Nicolaides KH
    . Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 2018;218:287–293.e1
    OpenUrl
  81. ↵
    1. Henderson JT,
    2. Whitlock EP,
    3. O’Conner E,
    4. Senger CA,
    5. Thompson JH,
    6. Rowland MG
    . Low-dose aspirin for the prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force, 2014. Rockville, MD, Agency for Healthcare Research and Quality (Report No. 14-05207-EF-1)
  82. ↵
    1. Werner EF,
    2. Hauspurg AK,
    3. Rouse DJ
    . A cost-benefit analysis of low-dose aspirin prophylaxis for the prevention of preeclampsia in the United States. Obstet Gynecol 2015;126:1242–1250
    OpenUrl
  83. ↵
    1. Voutetakis A,
    2. Pervanidou P,
    3. Kanaka-Gantenbein C
    . Aspirin for the prevention of preeclampsia and potential consequences for fetal brain development. JAMA Pediatr 2019;173:619–620
    OpenUrl
  84. ↵
    1. Brown MA,
    2. Magee LA,
    3. Kenny LC, et al
    .; International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 2018;72:24–43
    OpenUrlCrossRefPubMed
  85. ↵
    ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstet Gynecol 2019;133:e26–e50
    OpenUrl
  86. ↵
    1. Magee LA,
    2. von Dadelszen P,
    3. Rey E, et al
    . Less-tight versus tight control of hypertension in pregnancy. N Engl J Med 2015;372:407–417
    OpenUrlCrossRefPubMed
  87. ↵
    1. Sibai BM
    . Treatment of hypertension in pregnant women. N Engl J Med 1996;335:257–265
    OpenUrlCrossRefPubMedWeb of Science
  88. ↵
    1. Kazmin A,
    2. Garcia-Bournissen F,
    3. Koren G
    . Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can 2007;29:906–908
    OpenUrlCrossRefPubMed
  89. ↵
    1. Kim C,
    2. Newton KM,
    3. Knopp RH
    . Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002;25:1862–1868
    OpenUrlAbstract/FREE Full Text
  90. ↵
    1. Sutherland HW,
    2. Stowers JM
    1. Drury MI
    . Carbohydrate metabolism in pregnancy and the newborn. Sutherland HW, Stowers JM, Eds. Edinburgh, Churchill Livingstone, 1984
  91. ↵
    1. Tobias DK,
    2. Hu FB,
    3. Chavarro J,
    4. Rosner B,
    5. Mozaffarian D,
    6. Zhang C
    . Healthful dietary patterns and type 2 diabetes mellitus risk among women with a history of gestational diabetes mellitus. Arch Intern Med 2012;172:1566–1572
    OpenUrlCrossRefPubMedWeb of Science
  92. ↵
    1. Villamor E,
    2. Cnattingius S
    . Interpregnancy weight change and risk of adverse pregnancy outcomes: a population-based study. Lancet 2006;368:1164–1170
    OpenUrlCrossRefPubMedWeb of Science
  93. ↵
    1. Ratner RE,
    2. Christophi CA,
    3. Metzger BE, et al.; Diabetes Prevention Program Research Group
    . Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 2008;93:4774–4779
    OpenUrlCrossRefPubMedWeb of Science
  94. ↵
    1. Aroda VR,
    2. Christophi CA,
    3. Edelstein SL, et al.; Diabetes Prevention Program Research Group
    . The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. J Clin Endocrinol Metab 2015;100:1646–1653
    OpenUrlCrossRefPubMed
  95. ↵
    1. Achong N,
    2. Duncan EL,
    3. McIntyre HD,
    4. Callaway L
    . Peripartum management of glycemia in women with type 1 diabetes. Diabetes Care 2014;37:364–371
    OpenUrlAbstract/FREE Full Text
  96. ↵
    1. Roeder HA,
    2. Moore TR,
    3. Ramos GA
    . Changes in postpartum insulin requirements for patients with well-controlled type 1 diabetes. Am J Perinatol 2016;33:683–687
    OpenUrl
  97. ↵
    1. Riviello C,
    2. Mello G,
    3. Jovanovic LG
    . Breastfeeding and the basal insulin requirement in type 1 diabetic women. Endocr Pract 2009;15:187–193
    OpenUrlPubMed
  98. ↵
    1. Stuebe AM,
    2. Rich-Edwards JW,
    3. Willett WC,
    4. Manson JE,
    5. Michels KB
    . Duration of lactation and incidence of type 2 diabetes. JAMA 2005;294:2601–2610
    OpenUrlCrossRefPubMedWeb of Science
  99. ↵
    1. Pereira PF,
    2. Alfenas RdeCG,
    3. Araújo RMA
    . Does breastfeeding influence the risk of developing diabetes mellitus in children? A review of current evidence. J Pediatr (Rio J) 2014;90:7–15
    OpenUrlPubMed
PreviousNext
Back to top
Diabetes Care: 43 (Supplement 1)

In this Issue

January 2020, 43(Supplement 1)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Standards of Care (PDF)
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2020
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2020
American Diabetes Association
Diabetes Care Jan 2020, 43 (Supplement 1) S183-S192; DOI: 10.2337/dc20-S014

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2020
American Diabetes Association
Diabetes Care Jan 2020, 43 (Supplement 1) S183-S192; DOI: 10.2337/dc20-S014
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • DIABETES IN PREGNANCY
    • PRECONCEPTION COUNSELING
    • GLYCEMIC TARGETS IN PREGNANCY
    • MANAGEMENT OF GESTATIONAL DIABETES MELLITUS
    • MANAGEMENT OF PREEXISTING TYPE 1 DIABETES AND TYPE 2 DIABETES IN PREGNANCY
    • PREECLAMPSIA AND ASPIRIN
    • PREGNANCY AND DRUG CONSIDERATIONS
    • POSTPARTUM CARE
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • 7. Diabetes Technology: Standards of Medical Care in Diabetes—2020
  • 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
Show more Position Statements

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.